Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Beats Expectations By $0.58 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) issued its quarterly earnings results on Wednesday. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.58, Briefing.com reports. The business had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same quarter in the previous year, the business earned ($0.54) earnings per share.

Day One Biopharmaceuticals Trading Up 1.2 %

NASDAQ:DAWN traded up $0.17 during mid-day trading on Thursday, reaching $14.64. The company’s stock had a trading volume of 2,053,830 shares, compared to its average volume of 926,202. The firm’s fifty day moving average price is $14.16 and its two-hundred day moving average price is $14.38. The stock has a market cap of $1.28 billion, a P/E ratio of -7.42 and a beta of -1.51. Day One Biopharmaceuticals has a 12-month low of $10.90 and a 12-month high of $18.07.

Insider Transactions at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 3,202 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $44,828.00. Following the transaction, the general counsel now owns 26,928 shares in the company, valued at $376,992. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, General Counsel Adam Dubow sold 3,202 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the transaction, the general counsel now owns 26,928 shares in the company, valued at $376,992. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now owns 1,097,535 shares in the company, valued at $15,606,947.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,748 shares of company stock worth $689,072 over the last three months. 8.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on DAWN shares. JPMorgan Chase & Co. lowered their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday. Bank of America raised Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price target for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.